Navigation Links
Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Date:3/28/2012

AUSTIN, Texas, March 28, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced Dr. Amy Altman, vice president of Biodefense will present at the 5th National Bio-Threat Conference, taking place March 27-29, 2012 in Denver, Colorado. The meeting is sponsored by the Department of Defense's Joint Program Executive Office for Chemical and Biological Defense, Joint Project Manager Biological Defense, Joint Project Manager Guardian The Department of Homeland Security and the Environmental Protection Agency.(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

During the conference, Dr. Altman will present "MAGPIX®: A Compact, Robust LED-based xMAP® Analyzer for the Multiplex Detection of Bio-Threat Agents and Emerging Infectious Diseases" in Session 14: Latest and Greatest Chaired by Joseph Hamel, Department of Defense's Joint Program Manager, Biological Defense. Dr. Altman's presentation will take place on Wednesday, March 28, 2012 at 1:20 p.m. MDT at the Sheraton Denver Downtown, Plaza Ballroom E.

Providing nearly 5,000 data points in under an hour, MAGPIX was designed to meet the needs of laboratories, academic researchers and scientists who, until now, have been unable to take advantage of the power of multiplexing because of resource and space limitations.  The affordable LED-based system requires reduced sample reagents and hands-on time required for installation, operation and maintenance.  MAGPIX is easy to install out of the box and weighs less than 40 lbs., approximately 18 kg, making it simple and affordable to ship and deploy anywhere in the world. 

Dr. Altman will present MAGPIX data and provide commentary regarding on-board assay automation enhancements, allowing full automation from raw sample to answer.  MAGPIX has been tested in field tests conducted in a Technology Readiness Evaluation by the US Army Research, Development and Engineering Command Edgewood Chemical and Biological Center.

"Since its launch in July 2010, our innovative MAGPIX instrument has been well received in the marketplace.  This system provides an innovative, affordable option that is highly attractive to laboratories during the current challenging economic times," said Patrick Balthrop, president and CEO of Luminex.  "MAGPIX is opening new doors to laboratories, and we believe it has the same potential for detection of biothreat.  We are extremely proud not only of the versatility of our technology for use in multiple and diverse applications, but for our ability to provide solutions that advance healthcare, save lives and protect public safety."

The 5th National Bio-Threat Conference provides a forum for dialogue between government, industry, academia, and first responders to address critical issues in environmental sampling, bio-detection, clinical diagnostics, and biosurveillance.  Understanding that a critical component of combating biological threat is to ensure warfighters, first responders, and laboratory technicians are prepared and equipped, the conference offers first responders from military and civil defense the opportunity to exchange techniques, ideas and lessons learned, along with demonstrations of new and innovative equipment and methodologies.  For more information, please visit: 5th National Bio-Threat Conference 2012.

About Luminex Corporation
Luminex is committed to applying its passion for innovation to advancing healthcare and research worldwide. We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP® open-architecture, multi-analyte platform, and our MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com.Contacts

 Corporate:

Media: Harriss T. Currie

Mimi TorringtonChief Financial Officer and Vice President, Finance

Director, Marketing CommunicationsLuminex Corporation

Luminex Corporation hcurrie@luminexcorp.com

mtorrington@luminexcorp.com 512.219.8020

512.219.8020  

 Investors:

Aaron DeLucia 

Porter NovelliMatthew Scalo

Aaron.DeLucia@porternovelli.com Sr. Director, Investor Relations

512.241.2249Luminex Corporation

 mscalo@luminexcorp.com

 512.219.8020

 


'/>"/>
SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
2. Luminex Corporation to Present at JP Morgan Healthcare Conference
3. Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match®
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. Neogen Corporation Announces 2nd Quarter Results Conference Call
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
11. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
Breaking Biology Technology:
(Date:9/3/2020)... ... 2020 , ... Litmus Health , the research-ready infrastructure ... the company’s security practices has been completed. The assessment deemed Litmus infrastructure to ... reviewed Litmus’ processes and systems, assessing them to see whether they adhere to ...
(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is pleased to ... most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made the Inc. ... growth of 71 percent. , The Inc. 5000 list represents a unique look ...
Breaking Biology News(10 mins):